期刊文献+

抑制剂PI-103对786-O细胞株PI3K/Akt/mTOR信号通路的影响 被引量:2

The effect of PI-103 inhibitor on PI3K/Akt/mTOR signal pathway in 786-O cell lines
下载PDF
导出
摘要 目的:探讨抑制剂PI-103对786-O细胞株PI3K/Akt/mTOR信号通路的影响。方法:本文建立PI3K抑制剂作用786-O细胞模型,CCK-8法检测PI-103的IC50值,Western blot法检测PI-103作用后细胞内pAkt蛋白表达水平。结果:786-O细胞72 h的IC50为(9.06±0.06)μmol/L,在此浓度下,细胞内p-Akt蛋白的表达水平显著降低(P<0.01)。结论:PI-103通过抑制PI3K来调控PI3K/Akt/mTOR信号通路下游分子,此信号通路在肾细胞癌发生发展中起着重要作用,为肾细胞癌的分子靶向治疗提供理论依据。 Objective: To explore the effect of PI3K/Akt/mTOR signal pathway in 786-O cell lines by inhibitor PI-103. Methods: Establish PI3K inhibitor 786-O cell model,CCK-8 assay IC50 values of PI-103 and Western blot assay p-Akt protein expression level. Results: 786-O cells 72 h IC50 was( 9. 06 ± 0. 06) μmol/L,p-Akt protein expression level in the cells was significantly lower( P 0. 01). Conclusion: PI-103 regulates the PI3K/Akt/mTOR signal pathway through inhibition of PI3K. This signal pathway plays an important role in renal cell carcinoma,which can provide a theoretical basis for molecular targeted therapy of renal cell carcinoma.
出处 《河南医学研究》 CAS 2013年第5期649-651,共3页 Henan Medical Research
关键词 PI-103 肾透明细胞癌 PI3K AKT MTOR PI-103 renal clear cell carcinoma PI3K/Akt/mTOR
  • 相关文献

参考文献10

二级参考文献74

  • 1杜贤进,张杰.分子靶向药物舒尼替尼治疗肾细胞癌[J].世界临床药物,2009,30(11):657-661. 被引量:3
  • 2岳中瑾.肿瘤干细胞及肾癌相关研究进展[J].中华泌尿外科杂志,2005,26(8):573-575. 被引量:5
  • 3黄玉钿,张声,郑曦,吴钦穗,黄双月,杨发端.乳腺癌中黏着斑激酶、抑癌基因PTEN编码蛋白的表达与生物学行为相关性分析[J].中华实验外科杂志,2005,22(10):1201-1202. 被引量:8
  • 4Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med, 2002,347 : 1593-1603.
  • 5Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer, 2004,4.. 381-393.
  • 6Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma. Cancer, 1997,80:987-989.
  • 7Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumorsuppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A, 1994,91 : 9700-9704.
  • 8Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol, 2003,170 : 593-594.
  • 9Fabian MA, Biggs WH, Trieber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotech ,2005,23:329-336.
  • 10Raymond E, Faivre S, Vera C. Final results of phase I and pharmokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced ancers. Proc Am Soc Clin Onco, 2003,122 : 192.

共引文献66

同被引文献26

  • 1刘丽萍,于卉影,马东初.eIF4E的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):118-121. 被引量:6
  • 2Uzdensky AB,Demyanenko SV,Bibov MY. Signal transdue- tion in human cutaneous melanoma and target drugs [J].C urr Cancer Drug Targets, 2013,13 (8) : 843-866.
  • 3Lopez-Fauqued M,Gil R,Grueso J,et al. The dual PI3K/ mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of so rafenib- treated melanoma cells [J]. Int J Cancer,2010,126(7): 1549-1561.
  • 4Wu P, Hu YZ. PI3K/Akt/mTOR pathway inhibitors in can- cer: a perspective on clinical progress [J]. Curr Med Chem, 2010,17(35) :4326-4321.
  • 5Mazzoletti M,Bortolin F, Brunelli L, et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates [J]. Cancer Res, 2011,71 ( 13 ) : 4573-4584.
  • 6Saturno G,Valenti M,De Haven Brandon A,et al. Com- bining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer ceils via suppression of sur- vival signaling [J]. Oncotarget, 2013,4 (8) : 1185-1198.
  • 7Yi YW,Hong W,Kang HJ,et al. Inhibition of the PI3K/ AKT pathway potentiates cyt0toxieity of EGFR kinase in- hibitors in triple-negative breast eaneer cells [J]. J Cell Mol Med,2013,17(5) :648-656.
  • 8Santo EE,Stroeken P,Sluis PV,et al. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma [J]. Cancer Res,2013,73(7) :2189-2198.
  • 9Hsu RY, Chan CH, Spicer JD, et al. LPS-Induced TLR4 Signaling in Human Colorectal Cancer Cells Increases {beta}1 Integrin-Mediated Cell Adhesion and Liver Metastasis [J]. Cancer Res, 2011,71 (5) : 1989-1998.
  • 10Bagci-Onder T,Wakimoto H,Anderegg M,et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models [J]. Cancer Res,2011,71 (1) : 154-163.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部